Added to YB: 2026-06-29
Pitch date: 2026-06-25
ARGX [neutral]
argenx SE
-4.49%
current return
Author Info
Lux Opes Research covers European companies. Lots of them. Sign up for the newsletter.
Company Info
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally.
Market Cap
EUR 55.6B
Pitch Price
EUR 784.20
Price Target
N/A
Dividend
N/A
EV/EBITDA
38.93
P/E
39.77
EV/Sales
10.80
Sector
Biotechnology
Category
growth
Argenx (ARGX Belgium): Myositis could become the next major chapter for Vyvgart
ARGX (overview): Vyvgart maker eyeing myositis as next growth chapter, Phase III data due Q3. Phase II showed strong, fast efficacy in muscle strength/function w/ biomarker support. Mgmt splitting IMNM vs dermatomyositis for regulatory flexibility; durable LTE data. Part of Vision 2030 rheumatology push leveraging existing infra. Pipeline (empasiprubart, adimanebart) adds diversification. High expectations post strong run.
Read full article (2 min)